Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of the American College of Cardiology

• Publication date

  2008-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2007.10.048PMID 18308160PMCID PMC3096479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans

  2006cited by this paper
• Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis

  2006cited by this paper
• Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study

  2005cited by this paper
• Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

  2005cited by this paper
• Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres

  2004cited by this paper
• Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study

  2004cited by this paper
• Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany

  2004cited by this paper
• Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study

  2004influential reference
• Lipoprotein-Associated Phospholipase A

  2001cited by this paper
• A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.

  2001cited by this paper
• Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

  2000influential reference
• Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.

  1999cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Plasma Platelet-activating Factor Acetylhydrolase Is a Secreted Phospholipase A2 with a Catalytic Triad (*)

  1995cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Corrected group prognostic curves and summary statistics.

  1982cited by this paper
• Smoking and other risk factors for coronary heart-disease in British civil servants.

  1976cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.

  1962cited by this paper

• Sex-Specific Association Between Lp-PLA2 and Arterial Stiffness: A Cross-sectional Study

  2026cites this paper
• Diagnostic accuracy of the atherogenic index of plasma in metabolic syndrome: a diagnostic meta-analysis

  2025cites this paper
• Role of Serum Apelin and Carotid Artery Intima Thickness in Predicting Early Atherosclerotic Changes in Children With Beta–Thalassemia Major

  2025cites this paper
• The diagnostic value of lipoprotein-related phospholipase A2 and matrix metalloproteinase-9 in identifying patients with coronary plaque or stenosis

  2025cites this paper
• Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction

  2024cites this paper
• Liposomal-Associated Phospholipase A2 Is More Effective in Predicting Cardiac Risk in Law Enforcement Than Framingham Risk Score and Coronary Artery Calcium Score Calculation

  2024cites this paper
• Estimation of Low-Density Lipoprotein (LDL) values using equations and Machine Learning and variance calculation of LDL and Atherogenic Index of Plasma (AIP).

  2024cites this paper
• A randomized, double‐blind placebo‐controlled add‐on trial to assess the efficacy, safety, and anti‐atherogenic effect of spirulina platensis in patients with inadequately controlled type 2 diabetes mellitus

  2023cites this paper
• Is the Atherogenic Index of Plasma (AIP) a Cardiovascular Disease Marker?

  2023cites this paper
• Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation

  2022cites this paper
• Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study

  2021cites this paper
• Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients

  2021cites this paper
• Selected cardiovascular risk factors in early stages of chronic kidney disease

  2020cites this paper
• Elevated Lipoprotein-Associated Phospholipase A2 Independently Affects Age-Related Increases in Systolic Blood Pressure: A Nested Case-Control Study in a Prospective Korean Cohort

  2020cites this paper
• Grape seed extract supplementation along with a restricted‐calorie diet improves cardiovascular risk factors in obese or overweight adult individuals: A randomized, placebo‐controlled trial

  2020cites this paper
• Sudden Cardiac Death (SCD) – risk stratification and prediction with molecular biomarkers

  2019influential citation
• Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk

  2019cites this paper
• Association between atherogenic index of plasma and subclinical renal damage over a 12-year follow-up: Hanzhong adolescent hypertension study

  2019cites this paper
• Association of lipoprotein‐associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts

  2018cites this paper
• Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome

  2018cites this paper
• Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China

  2018cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk

  2018cites this paper
• Cardiovascular Risk Factors and Atherogenic Indices in an Iranian Population: Birjand East of Iran

  2018cites this paper
• PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders

  2018cites this paper
• Lipoprotein-Associated Phospholipase A2: A Risk Factor for Ischemic Stroke?

  2018cites this paper
• Calculated parameters of the lipidogram: modern scientific views and correlations with laboratory and instrumental indexes

  2017cites this paper
• Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

  2017cites this paper
• Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.

  2017cites this paper
• Are Cardiovascular Disease Inflammatory Markers Elevated in Those with Nonspecific Chronic Musculoskeletal Pain Compared to Nonpain Case Controls

  2017cites this paper
• Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.

  2017cites this paper
• Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population

  2017cites this paper
• Biomarkers to Predict Cardiovascular Death.

  2017cites this paper
• Inflammation and the Heart: A Commentary.

  2016cites this paper
• Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.

  2016cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A 2 ( Lp-PLA 2 ) in the Assessment of Cardiovascular Risk Policy

  2016cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A 2 ( Lp-PLA 2 ) in the Assessment of Cardiovascular Risk Policy

  2016cites this paper
• Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population

  2015cites this paper
• Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease

  2015cites this paper
• Screening for coronary artery disease in asymptomatic individuals: Why and how?

  2015cites this paper
• Lipoprotein-associated Phospholipase A2 is Associated with Angiographic Coronary Artery Disease and Coronary Artery Risk Factors in the Elderly

  2015cites this paper
• New Risk Factors of Cardiovascular Disease

  2015cites this paper
• The possibility of reducing the Lp-PLA2 mass level using simvastatin monotherapy and combination therapy with ezetimibe

  2015cites this paper
• НОВЫЕ ВОЗМОЖНОСТИ В ДИАГНОСТИКЕ ДЕКОМПЕНСИРОВАННОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ: КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ФАКТОРОВ РОСТА VEGF, PDGF(AB, FGF BASIC, ТКАНЕВОГО ИНГИБИТОРА МАТРИКСНЫХ МЕТАЛЛОПРОТЕИНАЗ 1 И ЛИПОПРОТЕИНАССОЦИИРОВАННОЙ ФОСФОЛИПАЗЫ А2

  2015cites this paper
• Novel biomarkers for cardiovascular risk assessment: current status and future directions.

  2015cites this paper
• Basic Principles of the Princeton Recommendations

  2015cites this paper
• Clinical Use of Serum Biomarkers in the Prediction of Cardiovascular Risk

  2015cites this paper
• Pericardial fat is associated with all-cause mortality but not incident CVD: the Rancho Bernardo Study.

  2015cites this paper
• Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

  2015cites this paper
• Biomarcadores relevantes para diagnóstico precoce e prevenção de doenças cardiovasculares.

  2014cites this paper
• Phospholipases in Cardiovascular Disease

  2014cites this paper
• An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.

  2014cites this paper
• Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population

  2014cites this paper
• Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia

  2014cites this paper
• Unraveling the PAF-AH/Lp-PLA2 controversy1

  2014cites this paper
• Critical appraisal of inflammatory markers in cardiovascular risk stratification

  2014cites this paper
• Biomarkers: Population Screening and Risk-Stratification

  2014cites this paper
• [Association of lipoprotein-associated phospholipase activity A2 with cardiovascular risk factors].

  2013cites this paper
• Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.

  2013cites this paper
• [Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].

  2013cites this paper
• Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): A Novel and Promising Biomarker for Cardiovascular Risks Assessment

  2013cites this paper
• Serum amyloid A stimulates lipoprotein-associated phospholipase A2 expression in vitro and in vivo.

  2013cites this paper
• [Clinical role of lipoprotein-associated phospholipase A2].

  2013cites this paper
• Measurement of Lipoprotein- Associated Phospholipase A2 (Lp- PLA2) in the Assessment of Cardiovascular Risk

  2013influential citation
• ACCF/AHA Practice Guideline

  2013cites this paper
• The Evaluation of New Biomarkers of Inflammation and Angiogenesis in Peripheral Arterial Disease

  2013cites this paper
• Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] study).

  2013cites this paper
• From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

  2012cites this paper
• Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

  2012cites this paper
• Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.

  2012cites this paper
• Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity.

  2012cites this paper
• The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

  2012cites this paper
• Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

  2012cites this paper
• Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker

  2012cites this paper
• Correlation between the lipid and cytokine profiles in patients with coronary heart disease (CHD) (Review article)

  2012cites this paper
• Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.

  2012cites this paper
• Identifying novel biomarkers for cardiovascular disease risk prediction

  2012cites this paper
• Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

  2012cites this paper
• Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.

  2012cites this paper
• The biological role of inflammation in atherosclerosis.

  2012cites this paper
• Lipoprotein-associated phospholipase A2 Mass and Activity and PLA2G7 gene polymorphisms as Markers for Cardiovascular Risk Stratification In High Risk Coronary Artery Disease Patients.

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases Modulation of oxidative stress, infl ammation, and atherosclerosis by lipoprotein-associated phospholipase A 2

  2012cites this paper
• Last Review Status/Date:

  2012cites this paper
• [Clinical factors and biomarkers associated with subclinical atherosclerosis in the human immunodeficiency virus infection].

  2012cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk-10/12

  2012cites this paper
• Koncentrace Lp-PLA2 u stabilních pacientů v sekundární prevenci po STEMI a vliv dávky statinů na její hodnoty

  2011cites this paper
• iii ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AND C-REACTIVE PROTEIN WITH MODERATE-TO-VIGOROUS PHYSICAL ACTIVITY IN MIDDLE-AGED WOMEN

  2011influential citation
• Guidelines Cardiology Foundation/American Heart Association Task Force on Practice of Asymptomatic Adults: Executive Summary: A Report of the American College 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in

  2011cites this paper
• Inflammatory markers in coronary heart disease.

  2011cites this paper
• Foundation/American Heart Association Task Force on Practice Guidelines Asymptomatic Adults : A Report of the American College of Cardiology 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in

  2011cites this paper
• The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease.

  2011cites this paper
• Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia

  2011cites this paper
• ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AND C- REACT IVE PROTEIN WITH MODERATE-TO-VIGOROUS PHYSICAL ACTIVITY IN MIDDLE-AGED WOMEN

  2011cites this paper
• Lp‐PLA2– a novel risk factor for high‐risk coronary and carotid artery disease

  2011cites this paper
• Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

  2011cites this paper
• 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary

  2010cites this paper
• Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Measurement of Inflammatory Risk: Independent or Complementary?

  2010cites this paper
• Phospholipase A2 as a therapeutic target for atherosclerosis

  2010cites this paper
• Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers

  2010cites this paper
• ACCF/AHA Practice Guideline Practice Guidelines 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults

  2010cites this paper
• 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2010cites this paper